LOVIT: Lessening Organ Dysfunction with VITamin C
LOVIT-COVID: Lessening Organ Dysfunction with VITamin C in COVID
What’s the purpose of these linked studies?
- These studies aim to determine whether the administration of intravenous vitamin C in patients hospitalized with COVID-19 improves their health status. Intravenous vitamin C may improve the complications of inflammation and dysfunction of small blood vessels in patients with COVID-19.
Who can participate in the studies?
- Patients ≥18 years old with a confirmed diagnosis of COVID-19 and who are admitted to hospital (ward or ICU). Participants must be enrolled in the first 24 hours of ICU admission, if on medications to raise blood pressure, to be eligible for LOVIT. Patients not on medications to raise their blood pressure but who are receiving non-invasive or invasive ventilation must be enrolled within 24 hours of starting ventilation. Patients on the medical ward are also eligible.
What’s involved in the studies?
Participants who meet all eligibility criteria will receive either:
- Experimental treatment: IV vitamin C 50 mg/kg every 6 hours for 96 hours, or
- Control treatment: IV placebo 50 mg/kg every 6 hours for 96 hours
Study urine and blood sample collection is coordinated with clinical care on study days 1, 3, and 7. Participants will also receive standard treatments as delivered by their healthcare team.
For more information, contact:
Principal Investigator Dr. Neill Adhikari, Department of Critical Care Medicine
Telephone: 416-480-4522
or contact the Critical Care Research Office at 416-480-6100 ext. 61719
